Patient
SITE004-0088
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE004 (DEU) (Dr. Tanaka)
consented 2025-12-13
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-25 (study day 185); relationship: not assessed
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-07-27 (study day 34); relationship: NOT RELATED
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-07-23 (study day 30); relationship: not assessed; serious criteria: life-threatening
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-07-19 (study day 26); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-08 (study day 15); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.